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A B S T R A C T
Purpose
Prolonged survival after two-stage resection (TSR) of advanced colorectal liver metastases (CLM)
may be the result of selection of best responders to chemotherapy. The impact of complete
resection in this well-selected group is controversial.
Patients and Methods
Data on 890 patients undergoing resection and 879 patients who received only chemotherapy for
CLM were collected prospectively. We used intent-to-treat analysis to evaluate the survival of
patients who underwent TSR. Additionally, we evaluated a cohort of nonsurgically treated patients
selected to mirror the TSR population: colorectal metastases with liver-only disease, objective
response to chemotherapy, and alive 1 year after chemotherapy initiation.
Results
Sixty-five patients underwent the first stage of TSR; 62 patients fulfilled the inclusion criteria for
the medical group. TSR patients had a mean of 6.7  3.4 CLM with mean size of 4.5  3.1 cm.
Nonsurgical patients had a mean of 5.9 2.9 CLM with mean size of 5.4 3.4 cm (not significant).
Forty-seven TSR patients (72%) completed the second stage. Progression between stages was
the main cause of noncompletion of the second stage (61%). After 50 months median follow-up,
the 5-year survival rate was 51% in the TSR group and 15% in the medical group (P  .005). In
patients who underwent TSR, noncompletion of TSR and major postoperative complications were
independently associated with worse survival.
Conclusion
TSR is associated with excellent outcome in patients with advanced CLM as a result of both
selection by chemotherapy and complete resection of metastatic disease.
J Clin Oncol 29:1083-1090. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Surgical resection is associated with long-term sur-
vival in patients with colorectal liver metastases
(CLM).1,2 The majority of patients with CLM pres-
ent with advancedmetastases at the time of diagno-
sis and therefore receive systemic chemotherapy.3,4
In patients with advanced CLM who have a suffi-
cient response to chemotherapy, an aggressive sur-
gical approach including two-stage resection (TSR)
has been proposed to improve outcome.5 Although
TSR has been associated with prolonged survival in
noncomparative surgical series,6-8 whether the sur-
vival benefit of this strategy results from complete
resection ofmetastatic disease or selection for resec-
tion of the best responders to chemotherapy is con-
troversial. In otherwords, is surgery really helpful in
patientswith advancedCLMwho respond to chem-
otherapy?What makes this question especially rele-
vant is that the TSR strategy has been introduced
during the same period as new, more effective cyto-
toxic agents (oxaliplatin and irinotecan) andmono-
clonal antibodies targeting the vascular endothelial
growth factor (bevacizumab) and the epidermal
growth factor receptor (cetuximab and panitu-
mumab).9-12 To date, the reported median overall
survival of patients with advanced colorectal cancer
who respond to these regimens has been asmuch as
31 months.13 A randomized trial comparing TSR
and continuation of chemotherapy in patients with
advanced bilateral CLM that respond to systemic
therapy may be impractical. We therefore con-
ducted this retrospective study to compare out-
comes of patients undergoing at least the first stage
of TSR with those of selected nonsurgically treated
patients responding tomodern chemotherapy.
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PATIENTS AND METHODS
Patient Population
From June 2002 to February 2010, data were prospectively collected on
890 consecutive patients who underwent surgical resection of CLM at one
institution and 879 consecutive patients with advanced colorectal cancer
treated with systemic chemotherapy only at the same institution.
For this study, for the surgically treated group, we selected all patients
who underwent at least the first stage of planned TSR of advanced bilateral
CLM. For the nonsurgically treated group, we selected patients who were
similar to the surgically treated patients in terms of performance status, ab-
sence of extrahepaticmetastases, extent of hepaticmetastases on pretreatment
imaging, and objective response to chemotherapy. In other words, we tried to
ensure similarity of the surgically treated and nonsurgically treated patient
groups. A similar selection process has previously been used to compare
surgical and medical populations when a prospective controlled trial is not
possible.3,14 For the medical population, we selected patients treated with
chemotherapy only who were alive at 1 year and who met the following
inclusion criteria: age younger than 70 years, Eastern Cooperative Oncology
Groupperformance status 0 to2, liver-onlymetastases excludingpatientswith
innumerableCLM,objective response tofirst-line chemotherapy consistingof
irinotecan or oxaliplatin with or without bevacizumab or cetuximab, no evi-
dence of bowel obstruction, and alive 1 year after chemotherapy initiation.
Pre- and post-treatment archived imaging of the patients was systematically
reviewed to ensure that theywere potential candidates forTSR (J.N.V., E.K.A.,
and A.B.). The study was approved by the institutional review board of The
University of TexasMDAnderson Cancer Center.
Systemic Chemotherapy
At theMDAndersonCancer Center, patients with advanced CLM initially
unsuitable for resection are seen by a surgeon before initiation of chemotherapy
to determine whether the patient may be a surgical candidate with a chemo-
sensitive tumor (one with a radiographic response to chemotherapy). In pa-
tients with advanced CLM who are identified before chemotherapy as being
potential candidates for surgery, resection is consideredonly if it canbecompleted
in stable disease (no change in size) or downsizedCLM (decrease in size).15 In all
patients receiving first-line chemotherapy, tumor response was assessed every
three to four cycles by using the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria and classified as complete response, partial response, stable
disease, or progressive disease16; beginning in 2009, tumor response was also
evaluated according tomorphologic criteria (none, incomplete, optimal).13
Two-Stage Liver Resection
TSR was proposed to patients with advanced bilateral CLM who re-
sponded to chemotherapy and in whom limited resection could clear the less
affected side of the liver before the patient underwent a planned extended
contralateral liver resection (Fig 1). TSR requires an area of the liver to be
relatively spared by disease because the surgeonmust be able to resect all CLM
while preserving a sufficient future liver remnant (20% of total liver volume)
and adequate vascular inflow and outflow.17 In the majority of patients who
werecandidates for andopted forTSR, theprogramincluded limited resection
of CLM located in the left liver followed by right portal vein embolization 1 to
2 weeks later and then an extended right hepatectomy. Portal ligation was not
used because most patients needed extended right hepatectomy and this type
of resection requires embolization of segment IV branches which cannot be
achieved by ligation.18,19 Interval chemotherapy was not used routinely to
avoid the risk associated with extended chemotherapy.20-22 In patients who
developed disease progression or recurrence after the first stage of liver resec-
tion, usually the second stage was postponed, systemic chemotherapy was
restarted, and response was reevaluated after three or four cycles of interval
chemotherapy to determine whether the second stage could eventually be
performed. Postoperative 30-day and 90-day morbidity and mortality were
recorded prospectively, and postoperative complications were classified ac-
cording to their severity.23 Pathologic response was assessed as previously
described.4 Briefly, complete pathologic response was defined as 0% viable
tumor cells in residual tumor, major pathologic response 1% to 49%, and
minor pathologic response 50%.4 After surgery, chemotherapy was usually
reintroduced to complete a total of 12 cycles, including both preoperative and
postoperative chemotherapy. Patients were reassessed every 4 months after
completion of the second stage of liver resection, and further treatment was
decided according to the findings at reassessment.
Statistical Analysis
Quantitative and qualitative variables were expressed as mean  stan-
dard deviation, median and range, and frequency. Overall and disease-free
survival were calculated by using the Kaplan-Meiermethod and compared by
using the log-rank test. Overall survival was calculated from the beginning of
chemotherapy in both surgically treated andmedically treated patients. Anal-
ysis of survival in surgical patients was done on an intent-to-treat basis and
includedpatientswhodied after surgery andpatientswhounderwent only the
first stageof liver resection. For thedetectionof factors associatedwith survival
in patients with advanced bilateral CLM undergoing at least the first stage of
TSR, univariate and multivariate analyses were used to examine the relation-
ship between overall survival and the following variables: type of primary
tumor (rectum v colon), regional nodemetastases (v nometastasis), carcino-
embryonic antigen plasma level, synchronous (vmetachronous) CLM, num-
ber ofCLM(up to 7 v 7CLM) as previously reported,7maximumCLMsize
( 5 cm v 5 cm), duration of preoperative chemotherapy ( 3months v
3 months), type of chemotherapy, cumulative postoperative morbidity, and
noncompletion (v completion) of TSR.
RESULTS
Clinicopathologic Features of Patients With Advanced
Bilateral CLM Who Underwent at Least the First
Stage of TSR
Clinicopathologic characteristics of the 65 patients with ad-
vanced bilateral CLM who underwent at least the first stage of TSR
are summarized in Table 1. Most of the patients (52 of 65; 80%) had
synchronousCLM.All patients received anoxaliplatin- or irinotecan-
containing preoperative chemotherapy regimen, and the median
number of chemotherapy cycles before first-stage liver resection was
six (range, two to 26 cycles). Only 23 patients (35%) received more
than six preoperative chemotherapy cycles.
Feasibility of Two-Stage Strategy
Intraoperative characteristics and postoperative outcomes of the
65 patients who underwent at least the first stage of TSR are summa-
rized in Table 2. No patient died within 90 days after the first stage
hepatectomy. Two patients (3%) developed major postoperative
complications: one required re-operation for severe wound infection
after rectal resection performed at the same time as the first stage, and
one patient developed severe postoperative renal insufficiency. Nine-
teen patients (29%) had resection of the primary tumor combined
with the first-stage hepatectomy. The postoperative complication rate
was significantly increased in patients undergoing resection of the
primary tumorcombinedwith thefirst stageof liver resection(eightof
19 [42%] v eight of 46 [17%]; P .03). Histopathologic examination
of CLMresected at the first stage indicated that 52 patients (80%) had
amajor response to chemotherapy.
Among the 65 patients who underwent the first-stage hepatec-
tomy, 47 patients (72%) underwent the second-stage hepatectomy, a
mean of 8 4weeks after the first stage. Intraoperative characteristics
and postoperative outcomes of these 47 patients are summarized in
Table 2. Of these 47 patients, nine (19%) developed progression of
CLMbetween the first and second stages andwere restarted on chem-
otherapy before completion of the second stage. In these patients, the
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Fig 1. Advanced bilateral colorectal liver
metastases at diagnosis (A), after preop-
erative chemotherapy with infusional fluo-
rouracil, leucovorin, and oxaliplatin plus
bevacizumab for five cycles (B), after the
first-stage hepatectomy (C), after right
portal vein embolization extended to seg-
ment IV (D), and after the second stage
hepatectomy (E). White arrows indicate
surgical defect after the first-stage hepa-
tectomy; black arrowheads indicate the
coils after right portal vein embolization
extended to segment IV.
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mean time interval between stages was significantly longer than in
patients who did not receive interval chemotherapy (17 2 weeks v
8 3 weeks, respectively; P .04). Thirty patients (64%) had com-
plete resection with negative margins at both stages. Postoperative
30-daymortality ratewas2%.Threepatients (6%)diedwithin90days
after the second-stage hepatectomy from irreversible postoperative
liver failure. Of these three patients, one patient had future liver rem-
nant growth from 19% to 21% (hypertrophy 5%), one patient was
expected to undergo a right hepatectomy but underwent an un-
planned extended right hepatectomy with a future liver remnant vol-
ume of 19% because of intraoperative findings of more advanced
disease, and the remaining patient had an adequate future liver rem-
nant volume but had significant intraoperative blood loss necessitat-
ing polytransfusion. Overall, major complications after first- or
second-stage resection occurred in 14 patients (22%).
Eighteen (33%) of the 65 patients who underwent the first stage
did not undergo the second stage. Of these 18 patients, 11 (61%) had
progression or recurrence, including disease progression of the CLM
to be resected (n 7), recurrence in the future liver remnant (n 3),
or progression of both CLM and extrahepatic metastases (n  1).
Imaging reevaluation after initiation of interval chemotherapy
showed that complete resection could not be performed. In the other
seven patients (39%) who did not undergo the second-stage hepatec-
tomy, the second stage could not be performed for technical reasons,
including an inadequate increase in future liver remnant volume after
portal vein embolization (n 3), an inadequate recovery after first-
stage hepatectomy (n 2), and postoperative (n 1) or postportal
vein embolization (n 1) partial portal vein thrombosis.
Influence of the Two-Stage Strategy on Outcome
of Patients With Advanced Bilateral CLM Who
Responded to Chemotherapy
From June 2002 to February 2010, among 879 consecutive pa-
tients who received only chemotherapy for advanced colorectal can-
cer, 62 (7%) fulfilled this study’s inclusion criteria for comparison
with the patients who underwent at least the first stage of TSR (Fig 2).
Table 1. Clinicopathologic Features of 65 Patients Who Underwent at Least the First Stage of Two-Stage Resection and 62 Patients Treated by
Chemotherapy Only
Feature
Two-Stage Resection
Strategy (n  65)
Chemotherapy Only
(n  62)
PNo. % No. %
Age, years N/S
Mean  SD 52  9 55  9
Median 52 54
Range 35-69 32-68
Sex N/S
Male 47 37
Female 18 25
Rectal primary tumor 18 28 11 18 N/S
Node positive 47 72 43 69 N/S
Synchronous liver metastases 52 80 52 84 N/S
No. of lesions N/S
Mean  SD 6.7  3.4 5.9  2.9
Median 6 5.5
Range 2-18 2-14
Tumor size, cm N/S
Mean  SD 4.5  3.1 5.4  3.4
Median 4 4
Range 1-15 1-17
First-line chemotherapy regimen
Fluorouracil  oxaliplatin 46 71 41 66 N/S
Fluorouracil  irinotecan 19 29 21 34 N/S
Bevacizumab-containing regimen 48 74 38 61 N/S
Multiple lines of preoperative chemotherapy 6 9 — —
No. of cycles of preoperative chemotherapy — —
Mean  SD 8  5.6
Median 6
Range 2-26
CEA plasma level, ng/mL (preoperative or after initial response) N/S
Mean  SD 397  2,232 255  1,254
Median 6 13
Range 1-17,000 1-9,740
Radiologic response using RECIST
Partial or complete response 28 62  .001
Stable disease 37 0
Portal vein embolization 45 70 — —
Abbreviations: N/S, not significant; SD, standard deviation; CEA, carcinoembryonic antigen; RECIST, Response Evaluation Criteria in Solid Tumors.
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Clinicopathologic features of these 62 patients are summarized in
Table 1. These patients were not statistically different from patients
who underwent at least one stage of the TSR except for RECIST
response to systemic therapy with all patients in the chemotherapy-
only group having partial response (Table 1).
After amedian of 50months follow-up, patientswhounderwent
at least the first stage of TSR had significantly improved survival
compared with patients who underwent only chemotherapy for ad-
vanced bilateral CLM (67% v 41% 3-year overall survival rate and
51% v 15%5-year overall survival rate;P .005; Fig 3A). The survival
advantage was prominent for patients who completed the second
stage of TSR (84% v 42% 3-year survival rate and 64% v 15% 5-year
survival rate, respectively;P .001). In contrast, therewas no survival
advantage for patients who underwent only the first stage (3-year
survival rate 13% for first stage only v 42% for chemotherapy only;
P  .12; Fig 3B). Twenty-nine of the 47 patients who underwent
complete TSR (62%) had developed recurrences by the time of last
follow-up. One-year, 3-year, and 5-year disease-free survival rates in
these patients were 39%, 20%, and 20%, respectively.
Factors Associated With Survival in Patients Who
Underwent at Least the First Stage of TSR
Results of univariate and multivariate analyses for predictors of
survival in patients with advanced bilateral CLM who underwent at
least the first stage of TSR are summarized in Table 3. Univariate
analysis showed that total number of CLM greater than seven and
noncompletion of the two-stage strategy were associated with shorter
survival. In multivariate analysis, the occurrence of major postopera-
tive complications after the first- or second-stage hepatectomy and
noncompletion of the two-stage strategy were independently associ-
ated with worse survival.
Table 2. Perioperative Characteristics in Patients Undergoing First-Stage
and Second-Stage Resection
Characteristic No. %
First-stage resection 65
Major liver resection ( three contiguous
liver segments) 2 3
Radiofrequency ablation 2 3
Associated resection of primary tumor 19 29
No. of lesions resected during first stage
Mean  SD 2  1.7
Median 1
Range 1-8
Largest diameter of tumors resected
during first stage in cm
Mean  SD 2  2
Median 1.4
Range 0.4-15
Estimated blood loss, mL
Mean  SD 215  222
Median 150
Range 50-1,300
Transfusion 1 2
Postoperative 90-day deaths 0 0
Postoperative complications 16 25
Major postoperative complications 2 3
Length of hospital stay, days
Mean  SD 7  2.4
Median 6
Range 4-14
Positive margins 10 15
Second-stage resection 47
Major liver resection ( three contiguous
liver segments) 40 85
Extended liver resection ( four
contiguous liver segments) 32 68
Type of resection
Right hemihepatectomy 8
Left hemihepatectomy 1
Extended right hepatectomy 22
Extended left hepatectomy 10
Segmental resection 6
Estimated blood loss, mL
Mean  SD 500  350
Median 400
Range 50-1,950
Transfusion 6 13
Postoperative 90-day deaths 3 6.4
Complications 23 49
Major complications 12 26
Hepatic insufficiency 4 6
Fluid collection 13 27
Length of hospital stay in days
Mean  SD 8  6.6
Median 7
Range 4-50
Positive margins 10 21
Abbreviation: SD, standard deviation.
Postoperative hepatic insufficiency was defined as bilirubin peak 7 mg/dL.23
Dead < 1 year
Follow-up < 1 year
Nonresponders
Innumerable CLM 
Treated with chemotherapy for advanced CRC
(N = 879)
Liver-only metastases
(n = 425, 47%) 
Responders alive > 12 months 
(n = 207, 23%) 
Eligible patients
(n = 179, 20%) 
Nonsurgical cohort
(n = 62, 7%) 
Age > 70
PS* > 2
Extrahepatic
metastases
Fig 2. Selection of patients with advanced bilateral colorectal liver metastases
(CLM) treated with chemotherapy for inclusion in the nonsurgically treated
population for this study. CRC, colorectal cancer. (*) Performance status (PS)
according to the Eastern Cooperative Oncology Group scoring system.
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DISCUSSION
This study indicates that complete TSR is associated with excellent
outcome in patients with advanced bilateral CLM who respond to
chemotherapy. Our findings demonstrate that the survival benefit
associated with this aggressive surgical approach is due not only to
selection by preoperative chemotherapy of patients with favorable
tumor biology but also to complete resection of metastatic disease.
Candidates for TSR are selected on the basis of the presenting extent
and location of bilateral CLM and the response to first-line chemo-
therapy. In the current study, all patients selected to undergoTSRhad
anobjectiveresponsetochemotherapyonimaging,andthegreatmajority
of them(80%)alsohadamajorpathologic response,which is recognized
asastrongpredictorof survival.4WefoundthatTSRwascompleted in47
(72%) of the 65 patients inwhom it was attempted. This result is consis-
tent with data from previously reported smaller series,6,7,24,25 in which
rates of completion of both stages ranged from69% to 78%.
In this study,weobserveda64%5-yearoverall survival rate in the
patients with advanced bilateral CLMwho underwent complete TSR.
To the best of our knowledge, our series of 47 patients is the largest
series of patients with advanced bilateral CLM undergoing complete
TSR reported to date. The survival rate for this group in our study
compares favorably with previously reported rates, which range from
35% to 50%.6,7,24,25 Additionally, we observed a 5-year survival rate of
15% in patients with advanced bilateral CLM who received chemo-
therapyonly. This is the highest survival rate reported in anonsurgical
cohort of patients with CLM. Although the study population repre-
sents a highly selected sample of patients with advanced colorectal
cancer, it highlights the overall improvement of prognosis with the
introductionofnewchemotherapy regimensused in this setting.3,13,14
This improvement in survival rates after chemotherapyprobably con-
tributes to the good outcomes reported in TSR series, including ours,
because TSR is offered only to responders to chemotherapy.6,7,24
However, our finding that patients who completed TSR had higher
survival rates than those in patients treated with chemotherapy only
shows that progress of chemotherapy and selection of good respond-
ers do not fully account for the survival benefit observed. In patients
who underwent resection of advanced CLM, complete resection of
metastatic disease also contributed to the observed survival benefit.
Thus, there was no benefit of attempted TSR if the strategy could not
be completed.
One of the limitations of TSR is the complexity of the approach,
which combines the difficulties associated with repeat hepatectomy
with the difficulties associatedwith surgery on a regenerative liver.We
report a 6% 90-day mortality rate and a 49%morbidity rate after the
second stage of hepatectomy. These results are consistent with previ-
ously reported mortality and morbidity rates after TSR, which range
from 0% to 9% and from 26% to 59%, respectively.6-8,24 The three
postoperative deaths in this series occurred as a consequence of liver
failure after second-stage extended right hepatectomy in patients who
underwent preoperative portal vein embolization. Two of the three
patient deaths occurred early in our experience in patients with either
an inadequate future liver remnant volume (intraoperative change in
treatment plan) or insufficient hypertrophy ( 5%) after portal vein
embolization. These undesirable events reaffirm the importance of
preoperative assessment and standardized requirements for minimal
volume andhypertrophy cutoffs for extended liver resection andhave
since been incorporated into revised guidelines for major hepatec-
tomy.26 Themorbidity after the first stage of resection is low,7 and the
first stage is generally not a threat to patients’ lives because major
complications are uncommon. However, maintaining a low compli-
cation rate after the first stage clearly must be a surgical priority since
cumulative major complication after first- or second-stage resection
was a strong predictor of survival. Major complications after the first
stage delay recovery, disrupt the treatment strategy, and eventually
compromise completion of the second stage. We also found that
combined resection of the primary tumor with the first stage of liver
resection was associated with an increased risk of complications. An
alternative inpatients inwhomtheprimary tumor isnonobstructive is
a reverse strategy in which the primary tumor is resected after com-
pletion of the two-stage strategy.27,28
This studyhas some limitations.We retrospectively analyzed two
subsets of patients treated medically and surgically and we cannot
exclude more advanced disease in patients treated medically despite
well-definedselectioncriteria.However, a randomizedcontrolled trial
in this setting isunlikelybecauseof the small subsetofpatientswhoare
potential candidates for this approach ( 10% of patients with ad-
vanced colorectal cancer). Taken together, our findings cannot be
used to define surgery and chemotherapy as opposing treatments;
rather, our findings can be used to define the impact of a sequenced
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Fig 3. Overall survival in patients with advanced bilateral colorectal liver
metastases (CLM) responding to chemotherapy enrolled in two-stage strategy
(intent-to-treat analysis including patients undergoing only the first stage of
two-stage hepatectomy) or receiving chemotherapy only (A) and stratified on the
basis of whether two-stage resection was completed (B).
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approach on a subset of patients with multiple bilateral CLM and
sufficient parenchymal sparing to a allow for a two-stage strategy.
In conclusion, this study showed that complete TSR is associated
with excellent outcome in patients with advanced bilateral CLMwho
respond to chemotherapy. The survival benefit associated with this
aggressive surgical approach is due to (1) selection of patients with
favorable tumor biology by preoperative chemotherapy, (2) selection
of patients with adequate liver hypertrophy and good performance
status, and (3) complete resection of metastatic disease. To further
improve the survival rate inpatientswhocompleteTSR, efforts should
focus on improved patient selection to increase the rate of success and
to lower morbidity.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Although all authors completed the disclosure declaration, the following
author(s) indicated a financial or other interest that is relevant to the subject
matter under consideration in this article. Certain relationships marked
with a “U” are those for which no compensation was received; those
relationships marked with a “C” were compensated. For a detailed
description of the disclosure categories, or for more information about
ASCO’s conflict of interest policy, please refer to the Author Disclosure
Declaration and the Disclosures of Potential Conflicts of Interest section in
Information for Contributors.
Employment or Leadership Position:None Consultant or Advisory
Role: Scott Kopetz, Roche (C); Michael J. Overman, Bristol-Myers
Squibb (C) Stock Ownership: NoneHonoraria: Scott Kopetz, Roche;
Cathy Eng, Genentech; Jean-Nicolas Vauthey, sanofi-aventis, Roche
Research Funding: Scott Kopetz, Roche; Michael J. Overman,
sanofi-aventis; Jean-Nicolas Vauthey, sanofi-aventis, Roche Expert
Testimony:NoneOther Remuneration:None
AUTHOR CONTRIBUTIONS
Conception and design: Antoine Brouquet, Eddie K. Abdalla, Scott
Kopetz, Jean-Nicolas Vauthey
Table 3. Univariate and Multivariate Analyses of Factors Associated With Survival in 65 Patients Who Underwent at Least the First Stage of Two-Stage
Liver Resection
Factor
No. of
Patients
5-Year
Survival (%)
Univariate
Analysis P
Multivariate
Analysis P HR 95% CI
Primary tumor .55
Rectal 18 48
Colon 47 52
Node .4
Positive 47 42
Negative 12 65
Unknown 6 75
CLM .1 .9
Synchronous 52 58
Metachronous 13 22
Total number of CLM .05 .18
 7 41 65
 7 24 26
Size of CLM, cm .3
 5 45 58
 5 20 31
Preoperative chemotherapy regimen .3
Fluorouracil  irinotecan 19 59
Fluorouracil  oxaliplatin 46 48
Bevacizumab .9
No 17 50
Yes 48 53
Preoperative chemotherapy duration, months .1 .7
 3 43 65
 3 22 15
CEA plasma level, ng/dL .3
 200 5 0
 200 60 54
No. of lesions resected during first stage .6
1 29 54
Multiple 36 46
Major postoperative complication after first or second resection .1 .04 3.1 1.1 to 9.2
Yes 14 55
No 51 33
Two-stage resection  .001 .001 7.2 2.4 to 22.4
Noncompletion 18 64
Completion 47 13
Abbreviations: HR, hazard ratio; CLM, colorectal liver metastases; CEA, carcinoembryonic antigen.
Resection of Advanced Colorectal Liver Metastases
www.jco.org © 2011 by American Society of Clinical Oncology 1089
Downloaded from jco.ascopubs.org on November 19, 2015. For personal use only. No other uses without permission.
Copyright © 2011 American Society of Clinical Oncology. All rights reserved.
Provision of study materials or patients: Eddie K. Abdalla, Christopher
R. Garrett, Michael J. Overman, Cathy Eng, David C. Madoff, Steven A.
Curley, Jean-Nicolas Vauthey
Collection and assembly of data: Antoine Brouquet, Eddie K. Abdalla,
Scott Kopetz, Jean-Nicolas Vauthey
Data analysis and interpretation:Antoine Brouquet, Eddie K. Abdalla,
Scott Kopetz, Christopher R. Garrett, Michael J. Overman, Cathy Eng,
EvelyneM. Loyer, David C.Madoff, Steven A. Curley, Jean-Nicolas Vauthey
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Scheele J, Stang R, Altendorf-Hofmann A, et
al: Resection of colorectal liver metastases. World
J Surg 19:59-71, 1995
2. Abdalla EK, Vauthey JN, Ellis LM, et al: Re-
currence and outcomes following hepatic resection,
radiofrequency ablation, and combined resection/
ablation for colorectal liver metastases. Ann Surg
239:818-825, 2004
3. Kopetz S, Chang GJ, Overman MJ, et al:
Improved survival in metastatic colorectal cancer is
associated with adoption of hepatic resection and
improved chemotherapy. J Clin Oncol 27:3677-
3683, 2009
4. Blazer DG 3rd, Kishi Y, Maru DM, et al:
Pathologic response to preoperative chemotherapy:
A new outcome end point after resection of hepatic
colorectal metastases. J Clin Oncol 26:5344-5351,
2008
5. Adam R, Laurent A, Azoulay D, et al: Two-
stage hepatectomy: A planned strategy to treat
irresectable liver tumors. Ann Surg 232:777-785,
2000
6. Wicherts DA, Miller R, de Haas RJ, et al:
Long-term results of two-stage hepatectomy for
irresectable colorectal cancer liver metastases. Ann
Surg 248:994-1005, 2008
7. Jaeck D, Oussoultzoglou E, Rosso E, et al: A
two-stage hepatectomy procedure combined with
portal vein embolization to achieve curative resec-
tion for initially unresectable multiple and bilobar
colorectal liver metastases. Ann Surg 240:1037-
1049, 2004; discussion 1049-1051
8. Chun YS, Vauthey JN, Ribero D, et al: Sys-
temic chemotherapy and two-stage hepatectomy
for extensive bilateral colorectal liver metastases:
Perioperative safety and survival. J Gastrointest
Surg 11:1498-1504, 2007; discussion 1504-1505
9. de Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxalipla-
tin as first-line treatment in advanced colorectal
cancer. J Clin Oncol 18:2938-2947, 2000
10. Douillard JY, Cunningham D, Roth AD, et al:
Irinotecan combined with fluorouracil compared
with fluorouracil alone as first-line treatment for
metastatic colorectal cancer: A multicentre ran-
domised trial. Lancet 355:1041-1047, 2000
11. Hurwitz H, Fehrenbacher L, Novotny W, et al:
Bevacizumab plus irinotecan, fluorouracil, and leuco-
vorin for metastatic colorectal cancer. N Engl J Med
350:2335-2342, 2004
12. Van Cutsem E, Ko¨hne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment
for metastatic colorectal cancer. N Engl J Med
360:1408-1417, 2009
13. Chun YS, Vauthey JN, Boonsirikamchai P, et
al: Association of computed tomography morpho-
logic criteria with pathologic response and survival in
patients treated with bevacizumab for colorectal
liver metastases. JAMA 302:2338-2344, 2009
14. Elias D, Lefevre JH, Chevalier J, et al: Com-
plete cytoreductive surgery plus intraperitoneal
chemohyperthermia with oxaliplatin for peritoneal
carcinomatosis of colorectal origin. J Clin Oncol
27:681-685, 2009
15. Adam R, Pascal G, Castaing D, et al: Tumor
progression while on chemotherapy: A contraindica-
tion to liver resection for multiple colorectal metas-
tases? Ann Surg 240:1052-1061, 2004; discussion
1061-1064
16. Therasse P, Arbuck SG, Eisenhauer EA, et al:
New guidelines to evaluate the response to treat-
ment in solid tumors: European Organization for
Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Insti-
tute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Charnsangavej C, Clary B, Fong Y, et al:
Selection of patients for resection of hepatic colo-
rectal metastases: Expert consensus statement.
Ann Surg Oncol 13:1261-1268, 2006
18. Kishi Y, Madoff DC, Abdalla EK, et al: Is
embolization of segment 4 portal veins before ex-
tended right hepatectomy justified? Surgery 144:
744-751, 2008
19. Madoff DC, Abdalla EK, Gupta S, et al: Trans-
hepatic ipsilateral right portal vein embolization ex-
tended to segment IV: Improving hypertrophy and
resection outcomes with spherical particles and
coils. J Vasc Interv Radiol 16:215-225, 2005
20. Vauthey JN, Pawlik TM, Ribero D, et al: Chem-
otherapy regimen predicts steatohepatitis and an
increase in 90-day mortality after surgery for hepatic
colorectal metastases. J Clin Oncol 24:2065-2072,
2006
21. Kishi Y, Zorzi D, Contreras CM, et al: Extended
preoperative chemotherapy does not improve pathologic
response and increases postoperative liver insufficiency
after hepatic resection for colorectal liver metastases.
Ann Surg Oncol 17:2870-2876, 2010
22. Chun YS, Laurent A, Maru D, et al: Manage-
ment of chemotherapy-associated hepatotoxicity in
colorectal liver metastases. Lancet Oncol 10:278-
286, 2009
23. Dindo D, Demartines N, Clavien PA: Classifi-
cation of surgical complications: A new proposal
with evaluation in a cohort of 6336 patients and
results of a survey. Ann Surg 240:205-213, 2004
24. Tsai S, Marques HP, de Jong MC, et al:
Two-stage strategy for patients with extensive bilat-
eral colorectal liver metastases. HPB (Oxford) 12:
262-269, 2010
25. Pamecha V, Nedjat-Shokouhi B, Gurusamy K,
et al: Prospective evaluation of two-stage hepatec-
tomy combined with selective portal vein embolisa-
tion and systemic chemotherapy for patients with
unresectable bilobar colorectal liver metastases. Dig
Surg 25:387-393, 2008
26. Kishi Y, Abdalla EK, Chun YS, et al: Three
hundred and one consecutive extended right hepa-
tectomies: Evaluation of outcome based on system-
atic liver volumetry. Ann Surg 250:540-548, 2009
27. Poultsides GA, Servais EL, Saltz LB, et al: Out-
come of primary tumor in patients with synchronous
stage IV colorectal cancer receiving combination chemo-
therapy without surgery as initial treatment. J Clin Oncol
27:3379-3384, 2009
28. Brouquet A, Mortenson MM, Vauthey JN, et
al: Surgical strategies for synchronous colorectal
liver metastases in 156 consecutive patients: Clas-
sic, combined or reverse strategy? J Am Coll Surg
210:934-941, 2010
■ ■ ■
Brouquet et al
1090 © 2011 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from jco.ascopubs.org on November 19, 2015. For personal use only. No other uses without permission.
Copyright © 2011 American Society of Clinical Oncology. All rights reserved.
